Oculis Holding AG (CR5.F)

12.10 +1.00 (+9.01%) At close: 03:29PM CEST

Oculis Holding AG

Bahnhofstrasse 7
Zug 6300
Switzerland
41 41 711 9325
https://oculis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 36

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Riad Sherif M.B.A., M.D.	CEO & Director	N/A	N/A	1968
Ms. Sylvia Cheung	Chief Financial Officer	N/A	N/A	1975
Dr. Ramin Tadayoni M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Virginia R. Dean	Chief Human Resources Officer	N/A	N/A	1967
Dr. Bastian Dehmel M.D.	Chief Development Officer	N/A	N/A	1971
Mr. Páll Ragnar Jóhannesson	Chief Business Officer	N/A	N/A	1982
Ms. Rebecca Weil	Chief Commercial Officer	N/A	N/A	N/A
Dr. Snehal Shah Pharm.D.	President of Research & Development	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Corporate governance

Oculis Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.